SEC 13F Intelligence

Brookmont Capital Management / ABT

Brookmont Capital Management’s Abbott Laboratories Position

Does Brookmont Capital Management own Abbott Laboratories (ABT)? Yes — 37.3K shares worth $4M (+2.14% of its 13F portfolio) as of Q1 2026, up from 35.8K shares the prior filed quarter.

Position Value
$4M
Q1 2026
Shares
37.3K
% of Portfolio
+2.14%
Quarters Held
30
currently held

Position History ABT

Reported value by quarter
Q4 ’18: $3MQ4 ’18Q1 ’19: $4MQ2 ’19: $4MQ3 ’19: $5MQ4 ’19: $4MQ4 ’19Q1 ’20: $4MQ2 ’20: $4MQ3 ’20: $4MQ4 ’20: $4MQ4 ’20Q1 ’21: $4MQ2 ’21: $4MQ3 ’21: $4MQ4 ’21: $5MQ4 ’21Q1 ’22: $4MQ2 ’22: $4MQ3 ’22: $4MQ4 ’22: $5MQ4 ’22Q1 ’23: $4MQ2 ’23: $5MQ3 ’23: $4MQ4 ’23: $5MQ4 ’23Q1 ’24: $5MQ2 ’24: $5MQ3 ’24: $5MQ4 ’24: $5MQ4 ’24Q1 ’25: $5MQ2 ’25: $5MQ3 ’25: $5MQ4 ’25: $4MQ4 ’25Q1 ’26: $4Mfilingsflow.com
QuarterSharesValue% of Portfolio
Q1 202637.3K$4M+2.14%
Q4 202535.8K$4M+2.60%
Q3 202536.0K$5M+2.68%
Q2 202538.1K$5M+2.97%
Q1 202539.3K$5M+2.94%
Q4 202442.1K$5M+2.54%
Q3 202442.6K$5M+2.50%
Q2 202444.1K$5M+2.51%
Q1 202444.3K$5M+2.65%
Q4 202344.1K$5M+2.72%
Q3 202344.0K$4M+2.66%
Q2 202341.3K$5M+2.72%
Q1 202341.4K$4M+2.64%
Q4 202241.2K$5M+2.78%
Q3 202237.9K$4M+2.55%
Q2 202235.4K$4M+2.65%
Q1 202235.4K$4M+2.51%
Q4 202135.1K$5M+2.62%
Q3 202136.8K$4M+2.57%
Q2 202137.0K$4M+2.59%
Q1 202136.9K$4M+2.85%
Q4 202037.4K$4M+2.89%
Q3 202040.6K$4M+3.28%
Q2 202040.1K$4M+2.93%
Q1 202049.7K$4M+3.16%
Q4 201950.7K$4M+2.63%
Q3 201954.7K$5M+2.61%
Q2 201947.1K$4M+2.38%
Q1 201947.0K$4M+2.31%
Q4 201847.0K$3M+2.31%

Common-stock position only; options are excluded. Quarters where the fund filed no 13F or reported no position are absent. See Brookmont Capital Management’s full portfolio or all institutional holders of ABT.